1. Home
  2. PFSA vs CLDI Comparison

PFSA vs CLDI Comparison

Compare PFSA & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PFSA
  • CLDI
  • Stock Information
  • Founded
  • PFSA 2009
  • CLDI 2014
  • Country
  • PFSA United States
  • CLDI United States
  • Employees
  • PFSA N/A
  • CLDI N/A
  • Industry
  • PFSA Medical/Dental Instruments
  • CLDI Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PFSA Health Care
  • CLDI Health Care
  • Exchange
  • PFSA Nasdaq
  • CLDI Nasdaq
  • Market Cap
  • PFSA 25.1M
  • CLDI 20.2M
  • IPO Year
  • PFSA N/A
  • CLDI N/A
  • Fundamental
  • Price
  • PFSA $0.40
  • CLDI $1.65
  • Analyst Decision
  • PFSA
  • CLDI
  • Analyst Count
  • PFSA 0
  • CLDI 0
  • Target Price
  • PFSA N/A
  • CLDI N/A
  • AVG Volume (30 Days)
  • PFSA 6.6M
  • CLDI 470.5K
  • Earning Date
  • PFSA 08-14-2025
  • CLDI 08-08-2025
  • Dividend Yield
  • PFSA N/A
  • CLDI N/A
  • EPS Growth
  • PFSA N/A
  • CLDI N/A
  • EPS
  • PFSA N/A
  • CLDI N/A
  • Revenue
  • PFSA $75,000.00
  • CLDI N/A
  • Revenue This Year
  • PFSA N/A
  • CLDI N/A
  • Revenue Next Year
  • PFSA N/A
  • CLDI N/A
  • P/E Ratio
  • PFSA N/A
  • CLDI N/A
  • Revenue Growth
  • PFSA 66.67
  • CLDI N/A
  • 52 Week Low
  • PFSA $0.38
  • CLDI $1.54
  • 52 Week High
  • PFSA $5.50
  • CLDI $46.68
  • Technical
  • Relative Strength Index (RSI)
  • PFSA N/A
  • CLDI 30.50
  • Support Level
  • PFSA N/A
  • CLDI $1.60
  • Resistance Level
  • PFSA N/A
  • CLDI $1.88
  • Average True Range (ATR)
  • PFSA 0.00
  • CLDI 0.48
  • MACD
  • PFSA 0.00
  • CLDI -0.24
  • Stochastic Oscillator
  • PFSA 0.00
  • CLDI 3.98

About PFSA Profusa Inc. Common Stock

Profusa Inc is a digital health technology company based in Emeryville, CA, that has developed a real-time, consumer-friendly platform that is designed to measure an individual's biochemistry, be easy to use, be cost-effective, and provide the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.

About CLDI Calidi Biotherapeutics Inc.

Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.

Share on Social Networks: